Home Nyheter Alligator Bioscience presents positive interim data

Alligator Bioscience presents positive interim data

Alligator Bioscience

Alligator Bioscience presents positive interim data

3 januari, 2023

Alligator Bioscience’s CEO Søren Bregenholt visited BioStock’s studio to talk about the promising interim data from the OPTIMIZE-1 phase II trial with mitazalimab in pancreatic cancer. The interim analysis shows an Objective Response Rate of 52 per cent and a Disease Control Rate of 91 per cent, further validating the potential of the drug candidate. Until the topline data is presented in Q1 2024, Alligator will continue the preparations for phase III and the dialogues with potential partners, as well as initiate discussions with regulatory authorities on possible accelerated development pathways.  

Watch the interview with Alligator Bioscience’s CEO Søren Bregenholt below.

YouTube video

Innehållet i BioStocks nyheter och analyser är oberoende men BioStocks verksamhet är i viss mån finansierad av bolag i branschen. Detta inlägg avser ett bolag som BioStock erhållit finansiering från.

Prenumerera på BioStocks nyhetsbrev

Dela gärna!